Lexeo Therapeutics, Inc.
LXEO
$4.61
-$0.12-2.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 75.52M | 74.09M | 63.94M | 57.76M | 52.43M |
| Gross Profit | -75.52M | -74.09M | -63.94M | -57.76M | -52.43M |
| SG&A Expenses | 40.76M | 31.68M | 29.42M | 24.33M | 20.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 116.28M | 105.77M | 93.36M | 82.09M | 72.51M |
| Operating Income | -116.28M | -105.77M | -93.36M | -82.09M | -72.51M |
| Income Before Tax | -109.31M | -98.33M | -86.60M | -77.22M | -69.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.31 | -98.33 | -86.60 | -77.22 | -69.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.31M | -98.33M | -86.60M | -77.22M | -69.42M |
| EBIT | -116.28M | -105.77M | -93.36M | -82.09M | -72.51M |
| EBITDA | -115.67M | -105.14M | -92.73M | -81.46M | -71.91M |
| EPS Basic | -3.31 | -3.09 | -3.17 | -14.64 | -22.30 |
| Normalized Basic EPS | -2.07 | -1.93 | -1.98 | -9.15 | -13.94 |
| EPS Diluted | -3.31 | -3.09 | -3.17 | -14.64 | -22.30 |
| Normalized Diluted EPS | -2.07 | -1.93 | -1.98 | -9.15 | -13.94 |
| Average Basic Shares Outstanding | 132.26M | 127.12M | 110.48M | 79.05M | 47.66M |
| Average Diluted Shares Outstanding | 132.26M | 127.12M | 110.48M | 79.05M | 47.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |